Similar articles for PMID: 21067352

Year	Number of Results
2009	3
2010	9
2011	18
2012	17
2013	9
2014	13
2015	11
2016	7
2017	4
2018	2
2019	3
2024	0

1

Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom.

Bate J, Yung CF, Hoschler K, Sheasby L, Morden J, Taj M, Heath PT, Miller E. Bate J, et al. Clin Infect Dis. 2010 Dec 15;51(12):e95-104. doi: 10.1086/657403. Epub 2010 Nov 10. Clin Infect Dis. 2010. PMID: 21067352

2

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.

Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW. Langley JM, et al. Pediatr Infect Dis J. 2012 Aug;31(8):848-58. doi: 10.1097/INF.0b013e31825e6cd6. Pediatr Infect Dis J. 2012. PMID: 22801094 Clinical Trial.

3

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, Gillard P, Arístegui J. Carmona A, et al. Vaccine. 2010 Aug 16;28(36):5837-44. doi: 10.1016/j.vaccine.2010.06.065. Epub 2010 Jun 29. Vaccine. 2010. PMID: 20600478 Clinical Trial.

4

The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children.

Okike IO, Yung C, Ladhani S, Oeser C, Bennett A, Doerholt K, Storey S, Donaghy S, Butter N, Hoschler K, Sheasby L, Heath PT, Miller E. Okike IO, et al. Vaccine. 2011 Sep 2;29(38):6636-40. doi: 10.1016/j.vaccine.2011.06.103. Epub 2011 Jul 13. Vaccine. 2011. PMID: 21742005

5

Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients.

Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, Bart PA, Venetz JP, Calandra T, Cavassini M. Manuel O, et al. Clin Infect Dis. 2011 Jan 15;52(2):248-56. doi: 10.1093/cid/ciq104. Clin Infect Dis. 2011. PMID: 21288852

6

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.

Waddington C, Andrews N, Hoschler K, Walker W, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston P, Allen R, Okike I, Ladhani S, Sheasby E, Waight P, Collinson A, Heath P, Finn A, Faust S, Snape M, Miller E, Pollard A. Waddington C, et al. Health Technol Assess. 2010 Oct;14(46):1-130. doi: 10.3310/hta14460-01. Health Technol Assess. 2010. PMID: 20923610 Free article. Clinical Trial.

7

Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.

Hoschler K, Andrews NJ, Faust SN, Finn A, Pollard AJ, Snape MD, Walker WT, Zambon M, Miller E. Hoschler K, et al. Clin Infect Dis. 2014 Jan;58(2):181-7. doi: 10.1093/cid/cit692. Epub 2013 Oct 22. Clin Infect Dis. 2014. PMID: 24149079

8

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.

Garcia-Sicilia J, Arístegui J, Omeñaca F, Carmona A, Tejedor JC, Merino JM, García-Corbeira P, Walravens K, Bambure V, Moris P, Caplanusi A, Gillard P, Dieussaert I. Garcia-Sicilia J, et al. Hum Vaccin Immunother. 2015;11(10):2359-69. doi: 10.1080/21645515.2015.1063754. Hum Vaccin Immunother. 2015. PMID: 26176592 Free PMC article. Clinical Trial.

9

Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G. Knuf M, et al. Vaccine. 2015 Jan 1;33(1):174-81. doi: 10.1016/j.vaccine.2014.10.085. Epub 2014 Nov 11. Vaccine. 2015. PMID: 25444803 Free article. Clinical Trial.

10

An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.

Poder A, Simurka P, Li P, Roy-Ghanta S, Vaughn D. Poder A, et al. Vaccine. 2014 Feb 19;32(9):1121-9. doi: 10.1016/j.vaccine.2013.11.031. Epub 2013 Nov 16. Vaccine. 2014. PMID: 24252703 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

88 results

Results by year